Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology.

Ju-Hee KangMagdalena KoreckaEdward B Lee Katheryn Alexandra Quilico Cousins Thomas Francis TropeaAlice A Chen-PlotkinDavid John IrwinDavid WolkMagdalena BrylskaYang WanLeslie M Shaw

Published in: Clinical chemistry (2023)

CSF AD biomarker measurements using fully automated analytical platforms is possible. Building on this experience, validated blood-based biomarker tests are being implemented on highly automated immunoassay and mass spectrometry platforms. The progress made developing analytically and clinically validated plasma AD biomarkers within the AT(N) classification scheme can accelerate use of AD biomarkers in therapeutic trials and routine clinical practice.

Keyphrases

clinical practice
deep learning
machine learning
mass spectrometry
liquid chromatography
high throughput
cerebrospinal fluid
mild cognitive impairment
label free
high resolution
loop mediated isothermal amplification
high performance liquid chromatography